



US009775546B2

(12) **United States Patent**
Diab et al.

(10) **Patent No.:** **US 9,775,546 B2**
(45) **Date of Patent:** ***Oct. 3, 2017**

(54) **HYPERSATURATION INDEX**
(71) Applicant: **MASIMO CORPORATION**, Irvine, CA (US)
(72) Inventors: **Mohamed K. Diab**, Ladera Ranch, CA (US); **Prashanth Iyengar**, Irvine, CA (US); **Anand Sampath**, Irvine, CA (US); **Ammar Al-Ali**, San Juan Capistrano, CA (US)
(73) Assignee: **MASIMO CORPORATION**, Irvine, CA (US)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.

(56) **References Cited**
U.S. PATENT DOCUMENTS
3,734,091 A 5/1973 Taplin
4,094,305 A 6/1978 Kessler
(Continued)
FOREIGN PATENT DOCUMENTS
EP 0329297 A2 8/1989
EP 0753320 A1 1/1997
WO WO 2013/158791 A3 10/2013
OTHER PUBLICATIONS
US 8,845,543, 09/2014, Diab et al. (withdrawn)
International Search Report and Written Opinion for PCT/US2013/037019 mailed Oct. 25, 2013 in 18 pages.

(21) Appl. No.: **14/852,356**
(22) Filed: **Sep. 11, 2015**


Primary Examiner — Eric Winakur
(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(65) **Prior Publication Data**
US 2016/0000362 A1 Jan. 7, 2016
Related U.S. Application Data
(63) Continuation of application No. 13/865,081, filed on Apr. 17, 2013, now Pat. No. 9,131,881.
(Continued)

(57) **ABSTRACT**
Embodiments of the present disclosure provide a hypersaturation index for measuring a patient's absorption of oxygen in the blood stream after a patient has reached 100% oxygen saturation. This hypersaturation index provides an indication of the partial pressure of oxygen of a patient. In an embodiment of the present invention, a hypersaturation index is calculated based on the absorption ratio of two different wavelengths of energy at a measuring site. In an embodiment of the invention, a maximum hypersaturation index threshold is determined such that an alarm is triggered when the hypersaturation index reaches or exceeds the threshold. In another embodiment, an alarm is triggered when the hypersaturation index reaches or falls below its starting point when it was first calculated.

(51) **Int. Cl.**
A61B 5/1455 (2006.01)
A61B 5/00 (2006.01)
A61B 5/0205 (2006.01)
(52) **U.S. Cl.**
CPC **A61B 5/14552** (2013.01); **A61B 5/0205** (2013.01); **A61B 5/14551** (2013.01);
(Continued)
(58) **Field of Classification Search**
CPC A61B 5/1445; A61B 5/14551; A61B 5/14552; A61B 5/7275
See application file for complete search history.

19 Claims, 16 Drawing Sheets



Related U.S. Application Data

(60) Provisional application No. 61/719,866, filed on Oct. 29, 2012, provisional application No. 61/703,087, filed on Sep. 19, 2012, provisional application No. 61/625,599, filed on Apr. 17, 2012.

(52) **U.S. Cl.**
 CPC *A61B 5/7282* (2013.01); *A61B 5/743* (2013.01); *A61B 5/7405* (2013.01); *A61B 5/746* (2013.01); *A61B 5/6826* (2013.01); *A61B 2562/0238* (2013.01); *A61M 2230/205* (2013.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,333,473	A	6/1982	Eberhard et al.
4,960,128	A	10/1990	Gordon et al.
4,964,408	A	10/1990	Hink et al.
5,041,187	A	8/1991	Hink et al.
5,069,213	A	12/1991	Polczynski
5,163,438	A	11/1992	Gordon et al.
5,184,618	A	2/1993	Wider et al.
5,319,355	A	6/1994	Russek
5,337,744	A	8/1994	Branigan
5,341,805	A	8/1994	Stavridi et al.
5,355,880	A	* 10/1994	Thomas A61B 5/1491 600/326
D353,195	S	12/1994	Savage et al.
D353,196	S	12/1994	Savage et al.
5,377,676	A	1/1995	Vari et al.
D359,546	S	6/1995	Savage et al.
5,431,170	A	7/1995	Mathews
D361,840	S	8/1995	Savage et al.
D362,063	S	9/1995	Savage et al.
5,452,717	A	9/1995	Branigan et al.
D363,120	S	10/1995	Savage et al.
5,456,252	A	10/1995	Vari et al.
5,479,934	A	1/1996	Imran
5,482,036	A	1/1996	Diab et al.
5,490,505	A	2/1996	Diab et al.
5,494,043	A	2/1996	O'Sullivan et al.
5,533,511	A	7/1996	Kaspari et al.
5,534,851	A	7/1996	Russek
5,561,275	A	10/1996	Savage et al.
5,562,002	A	10/1996	Lalin
5,590,649	A	1/1997	Caro et al.
5,602,924	A	2/1997	Durand et al.
5,632,272	A	5/1997	Diab et al.
5,638,816	A	6/1997	Kiani-Azarbayjany et al.
5,638,818	A	6/1997	Diab et al.
5,645,440	A	7/1997	Tobler et al.
5,685,299	A	11/1997	Diab et al.
D393,830	S	4/1998	Tobler et al.
5,743,262	A	4/1998	Lepper, Jr. et al.
5,758,644	A	6/1998	Diab et al.
5,760,910	A	6/1998	Lepper, Jr. et al.
5,769,785	A	6/1998	Diab et al.
5,782,757	A	7/1998	Diab et al.
5,785,659	A	7/1998	Caro et al.
5,791,347	A	8/1998	Flaherty et al.
5,810,734	A	9/1998	Caro et al.
5,823,950	A	10/1998	Diab et al.
5,830,131	A	11/1998	Caro et al.
5,833,618	A	11/1998	Caro et al.
5,860,919	A	1/1999	Kiani-Azarbayjany et al.
5,890,929	A	4/1999	Mills et al.
5,904,654	A	5/1999	Wohltmann et al.
5,919,134	A	7/1999	Diab
5,934,925	A	8/1999	Tobler et al.
5,940,182	A	8/1999	Lepper, Jr. et al.
5,995,855	A	11/1999	Kiani et al.
5,997,343	A	12/1999	Mills et al.
6,002,952	A	12/1999	Diab et al.

6,011,986	A	1/2000	Diab et al.
6,027,452	A	2/2000	Flaherty et al.
6,036,642	A	3/2000	Diab et al.
6,045,509	A	4/2000	Caro et al.
6,067,462	A	5/2000	Diab et al.
6,081,735	A	6/2000	Diab et al.
6,088,607	A	7/2000	Diab et al.
6,110,522	A	8/2000	Lepper, Jr. et al.
6,124,597	A	9/2000	Shehada
6,128,521	A	10/2000	Marro et al.
6,129,675	A	10/2000	Jay
6,144,868	A	11/2000	Parker
6,151,516	A	11/2000	Kiani-Azarbayjany et al.
6,152,754	A	11/2000	Gerhardt et al.
6,157,850	A	12/2000	Diab et al.
6,165,005	A	12/2000	Mills et al.
6,184,521	B1	2/2001	Coffin, IV et al.
6,206,830	B1	3/2001	Diab et al.
6,229,856	B1	5/2001	Diab et al.
6,232,609	B1	5/2001	Snyder et al.
6,236,872	B1	5/2001	Diab et al.
6,241,683	B1	6/2001	Macklem et al.
6,253,097	B1	6/2001	Aronow et al.
6,256,523	B1	7/2001	Diab et al.
6,263,222	B1	7/2001	Diab et al.
6,278,522	B1	8/2001	Lepper, Jr. et al.
6,280,213	B1	8/2001	Tobler et al.
6,285,896	B1	9/2001	Tobler et al.
6,301,493	B1	10/2001	Marro et al.
6,317,627	B1	11/2001	Ennen et al.
6,321,100	B1	11/2001	Parker
6,325,761	B1	12/2001	Jay
6,334,065	B1	12/2001	Al-Ali et al.
6,343,224	B1	1/2002	Parker
6,349,228	B1	2/2002	Kiani et al.
6,360,114	B1	3/2002	Diab et al.
6,368,283	B1	4/2002	Xu et al.
6,371,921	B1	4/2002	Caro et al.
6,377,829	B1	4/2002	Al-Ali
6,388,240	B2	5/2002	Schulz et al.
6,397,091	B2	5/2002	Diab et al.
6,430,437	B1	8/2002	Marro
6,430,525	B1	8/2002	Weber et al.
6,463,311	B1	10/2002	Diab
6,470,199	B1	10/2002	Kopotic et al.
6,501,975	B2	12/2002	Diab et al.
6,505,059	B1	1/2003	Kollias et al.
6,515,273	B2	2/2003	Al-Ali
6,519,487	B1	2/2003	Parker
6,525,386	B1	2/2003	Mills et al.
6,526,300	B1	2/2003	Kiani et al.
6,541,756	B2	4/2003	Schulz et al.
6,542,764	B1	4/2003	Al-Ali et al.
6,580,086	B1	6/2003	Schulz et al.
6,584,336	B1	6/2003	Ali et al.
6,595,316	B2	7/2003	Cybulski et al.
6,597,932	B2	7/2003	Tian et al.
6,597,933	B2	7/2003	Kiani et al.
6,606,511	B1	8/2003	Ali et al.
6,632,181	B2	10/2003	Flaherty et al.
6,639,668	B1	10/2003	Trepagnier
6,640,116	B2	10/2003	Diab
6,643,530	B2	11/2003	Diab et al.
6,650,917	B2	11/2003	Diab et al.
6,654,624	B2	11/2003	Diab et al.
6,658,276	B2	12/2003	Kiani et al.
6,661,161	B1	12/2003	Lanzo et al.
6,671,531	B2	12/2003	Al-Ali et al.
6,678,543	B2	1/2004	Diab et al.
6,684,090	B2	1/2004	Ali et al.
6,684,091	B2	1/2004	Parker
6,697,656	B1	2/2004	Al-Ali
6,697,657	B1	2/2004	Shehada et al.
6,697,658	B2	2/2004	Al-Ali
RE38,476	E	3/2004	Diab et al.
6,699,194	B1	3/2004	Diab et al.
6,714,804	B2	3/2004	Al-Ali et al.
RE38,492	E	4/2004	Diab et al.
6,721,582	B2	4/2004	Trepagnier et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,721,585	B1	4/2004	Parker	7,356,365	B2	4/2008	Schurman
6,725,075	B2	4/2004	Al-Ali	7,371,981	B2	5/2008	Abdul-Hafiz
6,728,560	B2	4/2004	Kollias et al.	7,373,193	B2	5/2008	Al-Ali et al.
6,735,459	B2	5/2004	Parker	7,373,194	B2	5/2008	Weber et al.
6,745,060	B2	6/2004	Diab et al.	7,376,453	B1	5/2008	Diab et al.
6,760,607	B2	7/2004	Al-Ali	7,377,794	B2	5/2008	Al Ali et al.
6,770,028	B1	8/2004	Ali et al.	7,377,899	B2	5/2008	Weber et al.
6,771,994	B2	8/2004	Kiani et al.	7,383,070	B2	6/2008	Diab et al.
6,792,300	B1	9/2004	Diab et al.	7,415,297	B2	8/2008	Al-Ali et al.
6,813,511	B2	11/2004	Diab et al.	7,428,432	B2	9/2008	Ali et al.
6,816,741	B2	11/2004	Diab	7,438,683	B2	10/2008	Al-Ali et al.
6,822,564	B2	11/2004	Al-Ali	7,440,787	B2	10/2008	Diab
6,826,419	B2	11/2004	Diab et al.	7,454,240	B2	11/2008	Diab et al.
6,830,711	B2	12/2004	Mills et al.	7,467,002	B2	12/2008	Weber et al.
6,850,787	B2	2/2005	Weber et al.	7,469,157	B2	12/2008	Diab et al.
6,850,788	B2	2/2005	Al-Ali	7,471,969	B2	12/2008	Diab et al.
6,852,083	B2	2/2005	Caro et al.	7,471,971	B2	12/2008	Diab et al.
6,861,639	B2	3/2005	Al-Ali	7,483,729	B2	1/2009	Al-Ali et al.
6,898,452	B2	5/2005	Al-Ali et al.	7,483,730	B2	1/2009	Diab et al.
6,920,345	B2	7/2005	Al-Ali et al.	7,489,958	B2	2/2009	Diab et al.
6,931,268	B1	8/2005	Kiani-Azarbayjany et al.	7,496,391	B2	2/2009	Diab et al.
6,934,570	B2	8/2005	Kiani et al.	7,496,393	B2	2/2009	Diab et al.
6,939,305	B2	9/2005	Flaherty et al.	D587,657	S	3/2009	Al-Ali et al.
6,943,348	B1	9/2005	Coffin, IV	7,499,741	B2	3/2009	Diab et al.
6,950,687	B2	9/2005	Al-Ali	7,499,835	B2	3/2009	Weber et al.
6,961,598	B2	11/2005	Diab	7,500,950	B2	3/2009	Al-Ali et al.
6,970,792	B1	11/2005	Diab	7,509,154	B2	3/2009	Diab et al.
6,979,812	B2	12/2005	Al-Ali	7,509,494	B2	3/2009	Al-Ali
6,985,764	B2	1/2006	Mason et al.	7,510,849	B2	3/2009	Schurman et al.
6,993,371	B2	1/2006	Kiani et al.	7,526,328	B2	4/2009	Diab et al.
6,996,427	B2	2/2006	Ali et al.	7,530,942	B1	5/2009	Diab
6,999,904	B2	2/2006	Weber et al.	7,530,949	B2	5/2009	Al Ali et al.
7,003,338	B2	2/2006	Weber et al.	7,530,955	B2	5/2009	Diab et al.
7,003,339	B2	2/2006	Diab et al.	7,563,110	B2	7/2009	Al-Ali et al.
7,015,451	B2	3/2006	Dalke et al.	7,596,398	B2	9/2009	Al-Ali et al.
7,024,233	B2	4/2006	Ali et al.	7,618,375	B2	11/2009	Flaherty
7,027,849	B2	4/2006	Al-Ali	D606,659	S	12/2009	Kiani et al.
7,030,749	B2	4/2006	Al-Ali	7,647,083	B2	1/2010	Al-Ali et al.
7,039,449	B2	5/2006	Al-Ali	D609,193	S	2/2010	Al-Ali et al.
7,041,060	B2	5/2006	Flaherty et al.	D614,305	S	4/2010	Al-Ali et al.
7,044,918	B2	5/2006	Diab	RE41,317	E	5/2010	Parker
7,067,893	B2	6/2006	Mills et al.	7,729,733	B2	6/2010	Al-Ali et al.
7,096,052	B2	8/2006	Mason et al.	7,734,320	B2	6/2010	Al-Ali
7,096,054	B2	8/2006	Abdul-Hafiz et al.	7,761,127	B2	7/2010	Al-Ali et al.
7,132,641	B2	11/2006	Schulz et al.	7,761,128	B2	7/2010	Al-Ali et al.
7,142,901	B2	11/2006	Kiani et al.	7,764,982	B2	7/2010	Dalke et al.
7,149,561	B2	12/2006	Diab	D621,516	S	8/2010	Kiani et al.
7,186,966	B2	3/2007	Al-Ali	7,791,155	B2	9/2010	Diab
7,190,261	B2	3/2007	Al-Ali	7,801,581	B2	9/2010	Diab
7,215,984	B2	5/2007	Diab	7,822,452	B2	10/2010	Schurman et al.
7,215,986	B2	5/2007	Diab	RE41,912	E	11/2010	Parker
7,221,971	B2	5/2007	Diab	7,844,313	B2	11/2010	Kiani et al.
7,225,006	B2	5/2007	Al-Ali et al.	7,844,314	B2	11/2010	Al-Ali
7,225,007	B2	5/2007	Al-Ali	7,844,315	B2	11/2010	Al-Ali
RE39,672	E	6/2007	Shehada et al.	7,865,222	B2	1/2011	Weber et al.
7,239,905	B2	7/2007	Kiani-Azarbayjany et al.	7,873,497	B2	1/2011	Weber et al.
7,245,953	B1	7/2007	Parker	7,880,606	B2	2/2011	Al-Ali
7,254,429	B2	8/2007	Schurman et al.	7,880,626	B2	2/2011	Al-Ali et al.
7,254,431	B2	8/2007	Al-Ali	7,891,355	B2	2/2011	Al-Ali et al.
7,254,433	B2	8/2007	Diab et al.	7,894,868	B2	2/2011	Al-Ali et al.
7,254,434	B2	8/2007	Schulz et al.	7,899,507	B2	3/2011	Al-Ali et al.
7,272,425	B2	9/2007	Al-Ali	7,899,518	B2	3/2011	Trepagnier et al.
7,274,955	B2	9/2007	Kiani et al.	7,904,132	B2	3/2011	Weber et al.
D554,263	S	10/2007	Al-Ali	7,909,772	B2	3/2011	Popov et al.
7,280,858	B2	10/2007	Al-Ali et al.	7,910,875	B2	3/2011	Al-Ali
7,289,835	B2	10/2007	Mansfield et al.	7,919,713	B2	4/2011	Al-Ali et al.
7,292,883	B2	11/2007	De Felice et al.	7,937,128	B2	5/2011	Al-Ali
7,295,866	B2	11/2007	Al-Ali	7,937,129	B2	5/2011	Mason et al.
7,328,053	B1	2/2008	Diab et al.	7,937,130	B2	5/2011	Diab et al.
7,332,784	B2	2/2008	Mills et al.	7,941,199	B2	5/2011	Kiani
7,340,287	B2	3/2008	Mason et al.	7,951,086	B2	5/2011	Flaherty et al.
7,341,559	B2	3/2008	Schulz et al.	7,957,780	B2	6/2011	Lamego et al.
7,343,186	B2	3/2008	Lamego et al.	7,962,188	B2	6/2011	Kiani et al.
D566,282	S	4/2008	Al-Ali et al.	7,962,190	B1	6/2011	Diab et al.
7,355,512	B1	4/2008	Al-Ali	7,976,472	B2	7/2011	Kiani
				7,988,637	B2	8/2011	Diab
				7,990,382	B2	8/2011	Kiani
				7,991,446	B2	8/2011	Ali et al.
				8,000,761	B2	8/2011	Al-Ali

(56)

References Cited

U.S. PATENT DOCUMENTS

8,008,088 B2	8/2011	Bellott et al.	8,504,128 B2	8/2013	Blank et al.
RE42,753 E	9/2011	Kiani-Azarbayjany et al.	8,509,867 B2	8/2013	Workman et al.
8,019,400 B2	9/2011	Diab et al.	8,515,509 B2	8/2013	Bruinsma et al.
8,028,701 B2	10/2011	Al-Ali et al.	8,523,781 B2	9/2013	Al-Ali
8,029,765 B2	10/2011	Bellott et al.	8,529,301 B2	9/2013	Al-Ali et al.
8,036,727 B2	10/2011	Schurman et al.	8,532,727 B2	9/2013	Ali et al.
8,036,728 B2	10/2011	Diab et al.	8,532,728 B2	9/2013	Diab et al.
8,046,040 B2	10/2011	Ali et al.	D692,145 S	10/2013	Al-Ali et al.
8,046,041 B2	10/2011	Diab et al.	8,547,209 B2	10/2013	Kiani et al.
8,046,042 B2	10/2011	Diab et al.	8,548,548 B2	10/2013	Al-Ali
8,048,040 B2	11/2011	Kiani	8,548,549 B2	10/2013	Schurman et al.
8,050,728 B2	11/2011	Al-Ali et al.	8,548,550 B2	10/2013	Al-Ali et al.
RE43,169 E	2/2012	Parker	8,560,032 B2	10/2013	Al-Ali et al.
8,118,620 B2	2/2012	Al-Ali et al.	8,560,034 B1	10/2013	Diab et al.
8,126,528 B2	2/2012	Diab et al.	8,570,167 B2	10/2013	Al-Ali
8,128,572 B2	3/2012	Diab et al.	8,570,503 B2	10/2013	Vo et al.
8,130,105 B2	3/2012	Al-Ali et al.	8,571,617 B2	10/2013	Reichgott et al.
8,145,287 B2	3/2012	Diab et al.	8,571,618 B1	10/2013	Lamego et al.
8,150,487 B2	4/2012	Diab et al.	8,571,619 B2	10/2013	Al-Ali et al.
8,175,672 B2	5/2012	Parker	8,577,431 B2	11/2013	Lamego et al.
8,180,420 B2	5/2012	Diab et al.	8,581,732 B2	11/2013	Al-Ali et al.
8,182,443 B1	5/2012	Kiani	8,584,345 B2	11/2013	Al-Ali et al.
8,185,180 B2	5/2012	Diab et al.	8,588,880 B2	11/2013	Abdul-Hafiz et al.
8,190,223 B2	5/2012	Al-Ali et al.	8,600,467 B2	12/2013	Al-Ali et al.
8,190,227 B2	5/2012	Diab et al.	8,606,342 B2	12/2013	Diab
8,203,438 B2	6/2012	Kiani et al.	8,626,255 B2	1/2014	Al-Ali et al.
8,203,704 B2	6/2012	Merritt et al.	8,630,691 B2	1/2014	Lamego et al.
8,204,566 B2	6/2012	Schurman et al.	8,634,889 B2	1/2014	Al-Ali et al.
8,219,172 B2	7/2012	Schurman et al.	8,641,631 B2	2/2014	Sierra et al.
8,224,411 B2	7/2012	Al-Ali et al.	8,652,060 B2	2/2014	Al-Ali
8,228,181 B2	7/2012	Al-Ali	8,663,107 B2	3/2014	Kiani
8,229,533 B2	7/2012	Diab et al.	8,666,468 B1	3/2014	Al-Ali
8,233,955 B2	7/2012	Al-Ali et al.	8,667,967 B2	3/2014	Al-Ali et al.
8,244,325 B2	8/2012	Al-Ali et al.	8,670,811 B2	3/2014	O'Reilly
8,255,026 B1	8/2012	Al-Ali	8,670,814 B2	3/2014	Diab et al.
8,255,027 B2	8/2012	Al-Ali et al.	8,676,286 B2	3/2014	Weber et al.
8,255,028 B2	8/2012	Al-Ali et al.	8,682,407 B2	3/2014	Al-Ali
8,260,577 B2	9/2012	Weber et al.	RE44,823 E	4/2014	Parker
8,265,723 B1	9/2012	McHale et al.	RE44,875 E	4/2014	Kiani et al.
8,274,360 B2	9/2012	Sampath et al.	8,690,799 B2	4/2014	Telfort et al.
8,301,217 B2	10/2012	Al-Ali et al.	8,700,112 B2	4/2014	Kiani
8,306,596 B2	11/2012	Schurman et al.	8,702,627 B2	4/2014	Telfort et al.
8,310,336 B2	11/2012	Muhsin et al.	8,706,179 B2	4/2014	Parker
8,315,683 B2	11/2012	Al-Ali et al.	8,712,494 B1	4/2014	MacNeish, III et al.
RE43,860 E	12/2012	Parker	8,715,206 B2	5/2014	Telfort et al.
8,337,403 B2	12/2012	Al-Ali et al.	8,718,735 B2	5/2014	Lamego et al.
8,346,330 B2	1/2013	Lamego	8,718,737 B2	5/2014	Diab et al.
8,353,842 B2	1/2013	Al-Ali et al.	8,718,738 B2	5/2014	Blank et al.
8,355,766 B2	1/2013	MacNeish, III et al.	8,720,249 B2	5/2014	Al-Ali
8,359,080 B2	1/2013	Diab et al.	8,721,541 B2	5/2014	Al-Ali et al.
8,364,223 B2	1/2013	Al-Ali et al.	8,721,542 B2	5/2014	Al-Ali et al.
8,364,226 B2	1/2013	Diab et al.	8,723,677 B1	5/2014	Kiani
8,374,665 B2	2/2013	Lamego	8,740,792 B1	6/2014	Kiani et al.
8,385,995 B2	2/2013	Al-Ali et al.	8,754,776 B2	6/2014	Poeze et al.
8,385,996 B2	2/2013	Smith et al.	8,755,535 B2	6/2014	Telfort et al.
8,388,353 B2	3/2013	Kiani et al.	8,755,856 B2	6/2014	Diab et al.
8,399,822 B2	3/2013	Al-Ali	8,755,872 B1	6/2014	Marinow
8,401,602 B2	3/2013	Kiani	8,761,850 B2	6/2014	Lamego
8,405,608 B2	3/2013	Al-Ali et al.	8,764,671 B2	7/2014	Kiani
8,414,499 B2	4/2013	Al-Ali et al.	8,768,423 B2	7/2014	Shakespeare et al.
8,418,524 B2	4/2013	Al-Ali	8,771,204 B2	7/2014	Telfort et al.
8,423,106 B2	4/2013	Lamego et al.	8,777,634 B2	7/2014	Kiani et al.
8,428,967 B2	4/2013	Olsen et al.	8,781,543 B2	7/2014	Diab et al.
8,430,817 B1	4/2013	Al-Ali et al.	8,781,544 B2	7/2014	Al-Ali et al.
8,437,825 B2	5/2013	Dalvi et al.	8,781,549 B2	7/2014	Al-Ali et al.
8,455,290 B2	6/2013	Siskavich	8,788,003 B2	7/2014	Schurman et al.
8,457,703 B2	6/2013	Al-Ali	8,790,268 B2	7/2014	Al-Ali
8,457,707 B2	6/2013	Kiani	8,801,613 B2	8/2014	Al-Ali et al.
8,463,349 B2	6/2013	Diab et al.	8,821,397 B2	9/2014	Al-Ali et al.
8,466,286 B2	6/2013	Bellot et al.	8,821,415 B2	9/2014	Al-Ali et al.
8,471,713 B2	6/2013	Poeze et al.	8,830,449 B1	9/2014	Lamego et al.
8,473,020 B2	6/2013	Kiani et al.	8,831,700 B2	9/2014	Schurman et al.
8,483,787 B2	7/2013	Al-Ali et al.	8,840,549 B2	9/2014	Al-Ali et al.
8,489,364 B2	7/2013	Weber et al.	8,847,740 B2	9/2014	Kiani et al.
8,498,684 B2	7/2013	Weber et al.	8,849,365 B2	9/2014	Smith et al.
			8,852,094 B2	10/2014	Al-Ali et al.
			8,852,994 B2	10/2014	Wojtczuk et al.
			8,868,147 B2	10/2014	Stippick et al.
			8,868,150 B2	10/2014	Al-Ali et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,870,792 B2	10/2014	Al-Ali et al.	9,364,181 B2	6/2016	Kiani et al.
8,886,271 B2	11/2014	Kiani et al.	9,368,671 B2	6/2016	Wojtczuk et al.
8,888,539 B2	11/2014	Al-Ali et al.	9,370,325 B2	6/2016	Al-Ali et al.
8,888,708 B2	11/2014	Diab et al.	9,370,326 B2	6/2016	McHale et al.
8,892,180 B2	11/2014	Weber et al.	9,370,335 B2	6/2016	Al-Ali et al.
8,897,847 B2	11/2014	Al-Ali	9,375,185 B2	6/2016	Ali et al.
8,909,310 B2	12/2014	Lamego et al.	2005/0197551 A1	9/2005	Al-Ali et al.
8,911,377 B2	12/2014	Al-Ali	2008/0097173 A1	4/2008	Soyemi et al.
8,912,909 B2	12/2014	Al-Ali et al.	2009/0247984 A1	10/2009	Lamego et al.
8,920,317 B2	12/2014	Al-Ali et al.	2009/0275844 A1	11/2009	Al-Ali
8,921,699 B2	12/2014	Al-Ali et al.	2010/0004518 A1	1/2010	Vo et al.
8,922,382 B2	12/2014	Al-Ali et al.	2010/0030040 A1	2/2010	Poeze et al.
8,929,964 B2	1/2015	Al-Ali et al.	2010/0261979 A1	10/2010	Kiani
8,942,777 B2	1/2015	Diab et al.	2010/0331639 A1	12/2010	O'Reilly
8,948,834 B2	2/2015	Diab et al.	2011/0001605 A1	1/2011	Kiani et al.
8,948,835 B2	2/2015	Diab	2011/0082711 A1	4/2011	Poeze et al.
8,965,471 B2	2/2015	Lamego	2011/0105854 A1	5/2011	Kiani et al.
8,983,564 B2	3/2015	Al-Ali	2011/0208015 A1	8/2011	Welch et al.
8,989,831 B2	3/2015	Al-Ali et al.	2011/0213212 A1	9/2011	Al-Ali
8,996,085 B2	3/2015	Kiani et al.	2011/0230733 A1	9/2011	Al-Ali
8,998,809 B2	4/2015	Kiani	2011/0237911 A1	9/2011	Lamego et al.
9,028,429 B2	5/2015	Telfort et al.	2011/0295093 A1	12/2011	Graboi et al.
9,037,207 B2	5/2015	Al-Ali et al.	2012/0059267 A1	3/2012	Lamego et al.
9,060,721 B2	6/2015	Reichgott et al.	2012/0116175 A1	5/2012	Al-Ali et al.
9,066,666 B2	6/2015	Kiani	2012/0179006 A1	7/2012	Jansen et al.
9,066,680 B1	6/2015	Al-Ali et al.	2012/0209082 A1	8/2012	Al-Ali
9,072,474 B2	7/2015	Al-Ali et al.	2012/0209084 A1	8/2012	Olsen et al.
9,078,560 B2	7/2015	Schurman et al.	2012/0227739 A1	9/2012	Kiani
9,084,569 B2	7/2015	Weber et al.	2012/0283524 A1	11/2012	Kiani et al.
9,095,316 B2	8/2015	Welch et al.	2012/0296178 A1	11/2012	Lamego et al.
9,106,038 B2	8/2015	Telfort et al.	2012/0319816 A1	12/2012	Al-Ali
9,107,625 B2	8/2015	Telfort et al.	2012/0330112 A1	12/2012	Lamego et al.
9,107,626 B2	8/2015	Al-Ali et al.	2013/0023775 A1	1/2013	Lamego et al.
9,113,831 B2	8/2015	Al-Ali	2013/0041591 A1	2/2013	Lamego
9,113,832 B2	8/2015	Al-Ali	2013/0045685 A1	2/2013	Kiani
9,119,595 B2	9/2015	Lamego	2013/0046204 A1	2/2013	Lamego et al.
9,131,881 B2	9/2015	Diab et al.	2013/0060147 A1	3/2013	Welch et al.
9,131,882 B2	9/2015	Al-Ali et al.	2013/0096405 A1	4/2013	Garfio
9,131,883 B2	9/2015	Al-Ali	2013/0096936 A1	4/2013	Sampath et al.
9,131,917 B2	9/2015	Telfort et al.	2013/0109935 A1	5/2013	Al-Ali et al.
9,138,180 B1	9/2015	Coverston et al.	2013/0162433 A1	6/2013	Muhsin et al.
9,138,182 B2	9/2015	Al-Ali et al.	2013/0190581 A1	7/2013	Al-Ali et al.
9,138,192 B2	9/2015	Weber et al.	2013/0197328 A1	8/2013	Diab et al.
9,142,117 B2	9/2015	Muhsin et al.	2013/0211214 A1	8/2013	Olsen
9,153,112 B1	10/2015	Kiani et al.	2013/0243021 A1	9/2013	Siskavich
9,153,121 B2	10/2015	Kiani et al.	2013/0253334 A1	9/2013	Al-Ali et al.
9,161,696 B2	10/2015	Al-Ali et al.	2013/0274571 A1	10/2013	Diab et al.
9,161,713 B2	10/2015	Al-Ali et al.	2013/0296672 A1	11/2013	O'Neil et al.
9,167,995 B2	10/2015	Lamego et al.	2013/0317370 A1	11/2013	Dalvi et al.
9,176,141 B2	11/2015	Al-Ali et al.	2013/0324808 A1	12/2013	Al-Ali et al.
9,186,102 B2	11/2015	Bruinsma et al.	2013/0331670 A1	12/2013	Kiani
9,192,312 B2	11/2015	Al-Ali	2013/0338461 A1	12/2013	Lamego et al.
9,192,329 B2	11/2015	Al-Ali	2014/0012100 A1	1/2014	Al-Ali et al.
9,192,351 B1	11/2015	Telfort et al.	2014/0025306 A1	1/2014	Weber et al.
9,195,385 B2	11/2015	Al-Ali et al.	2014/0034353 A1	2/2014	Al-Ali et al.
9,211,072 B2	12/2015	Kiani	2014/0051953 A1	2/2014	Lamego et al.
9,211,095 B1	12/2015	Al-Ali	2014/0058230 A1	2/2014	Abdul-Hafiz et al.
9,218,454 B2	12/2015	Kiani et al.	2014/0066783 A1	3/2014	Kiani et al.
9,226,696 B2	1/2016	Kiani	2014/0077956 A1	3/2014	Sampath et al.
9,241,662 B2	1/2016	Al-Ali et al.	2014/0081100 A1	3/2014	Muhsin et al.
9,245,668 B1	1/2016	Vo et al.	2014/0081175 A1	3/2014	Telfort
9,259,185 B2	2/2016	Abdul-Hafiz et al.	2014/0094667 A1	4/2014	Schurman et al.
9,267,572 B2	2/2016	Barker et al.	2014/0100434 A1	4/2014	Diab et al.
9,277,880 B2	3/2016	Poeze et al.	2014/0114199 A1	4/2014	Lamego et al.
9,289,167 B2	3/2016	Diab et al.	2014/0120564 A1	5/2014	Workman et al.
9,295,421 B2	3/2016	Kiani et al.	2014/0121482 A1	5/2014	Merritt et al.
9,307,928 B1	4/2016	Al-Ali et al.	2014/0121483 A1	5/2014	Kiani
9,323,894 B2	4/2016	Kiani	2014/0127137 A1	5/2014	Bellott et al.
D755,392 S	5/2016	Hwang et al.	2014/0128696 A1	5/2014	Al-Ali
9,326,712 B1	5/2016	Kiani	2014/0128699 A1	5/2014	Al-Ali et al.
9,333,316 B2	5/2016	Kiani	2014/0129702 A1	5/2014	Lamego et al.
9,339,220 B2	5/2016	Lamego et al.	2014/0135588 A1	5/2014	Al-Ali et al.
9,341,565 B2	5/2016	Lamego et al.	2014/0142401 A1	5/2014	Al-Ali et al.
9,351,673 B2	5/2016	Diab et al.	2014/0142402 A1	5/2014	Al-Ali et al.
9,351,675 B2	5/2016	Al-Ali et al.	2014/0163344 A1	6/2014	Al-Ali
			2014/0163402 A1	6/2014	Lamego et al.
			2014/0166076 A1	6/2014	Kiani et al.
			2014/0171763 A1	6/2014	Diab
			2014/0180038 A1	6/2014	Kiani

(56)

References Cited

U.S. PATENT DOCUMENTS

2014/0180154	A1	6/2014	Sierra et al.	2015/0099955	A1	4/2015	Al-Ali et al.
2014/0194709	A1	7/2014	Al-Ali et al.	2015/0101844	A1	4/2015	Al-Ali et al.
2014/0194711	A1	7/2014	Al-Ali	2015/0106121	A1	4/2015	Muhsin et al.
2014/0194766	A1	7/2014	Al-Ali et al.	2015/0112151	A1	4/2015	Muhsin et al.
2014/0206963	A1	7/2014	Al-Ali	2015/0116076	A1	4/2015	Al-Ali et al.
2014/0213864	A1	7/2014	Abdul-Hafiz et al.	2015/0126830	A1	5/2015	Schurman et al.
2014/0243627	A1	8/2014	Diab et al.	2015/0133755	A1	5/2015	Smith et al.
2014/0266790	A1	9/2014	Al-Ali et al.	2015/0140863	A1	5/2015	Al-Ali et al.
2014/0275808	A1	9/2014	Poeze et al.	2015/0141781	A1	5/2015	Weber et al.
2014/0275835	A1	9/2014	Lamego et al.	2015/0165312	A1	6/2015	Kiani
2014/0275871	A1	9/2014	Lamego et al.	2015/0196237	A1	7/2015	Lamego
2014/0275872	A1	9/2014	Merritt et al.	2015/0201874	A1	7/2015	Diab
2014/0275881	A1	9/2014	Lamego et al.	2015/0208966	A1	7/2015	Al-Ali
2014/0288400	A1	9/2014	Diab et al.	2015/0216459	A1	8/2015	Al-Ali et al.
2014/0296664	A1	10/2014	Bruinsma et al.	2015/0230755	A1	8/2015	Al-Ali et al.
2014/0303520	A1	10/2014	Telfort et al.	2015/0238722	A1	8/2015	Al-Ali
2014/0309506	A1	10/2014	Lamego et al.	2015/0245773	A1	9/2015	Lamego et al.
2014/0316217	A1	10/2014	Purdon et al.	2015/0245794	A1	9/2015	Al-Ali
2014/0316218	A1	10/2014	Purdon et al.	2015/0257689	A1	9/2015	Al-Ali et al.
2014/0316228	A1	10/2014	Blank et al.	2015/0272514	A1	10/2015	Kiani et al.
2014/0323825	A1	10/2014	Al-Ali et al.	2015/0351697	A1	12/2015	Weber et al.
2014/0330092	A1	11/2014	Al-Ali et al.	2015/0351704	A1	12/2015	Kiani et al.
2014/0330098	A1	11/2014	Merritt et al.	2015/0359429	A1	12/2015	Al-Ali et al.
2014/0330099	A1	11/2014	Al-Ali et al.	2015/0366472	A1	12/2015	Kiani
2014/0333440	A1	11/2014	Kiani	2015/0366507	A1	12/2015	Blank
2014/0336481	A1	11/2014	Shakespeare et al.	2015/0374298	A1	12/2015	Al-Ali et al.
2014/0343436	A1	11/2014	Kiani	2015/0380875	A1	12/2015	Coverston et al.
2014/0357966	A1	12/2014	Al-Ali et al.	2016/0000362	A1	1/2016	Diab et al.
2014/0371548	A1	12/2014	Al-Ali et al.	2016/0007930	A1	1/2016	Weber et al.
2014/0371632	A1	12/2014	Al-Ali et al.	2016/0029932	A1	2/2016	Al-Ali
2014/0378784	A1	12/2014	Kiani et al.	2016/0029933	A1	2/2016	Al-Ali et al.
2015/0005600	A1	1/2015	Blank et al.	2016/0045118	A1	2/2016	Kiani
2015/0011907	A1	1/2015	Purdon et al.	2016/0051205	A1	2/2016	Al-Ali et al.
2015/0012231	A1	1/2015	Poeze et al.	2016/0058338	A1	3/2016	Schurman et al.
2015/0018650	A1	1/2015	Al-Ali et al.	2016/0058347	A1	3/2016	Reichgott et al.
2015/0025406	A1	1/2015	Al-Ali	2016/0066823	A1	3/2016	Al-Ali et al.
2015/0032029	A1	1/2015	Al-Ali et al.	2016/0066824	A1	3/2016	Al-Ali et al.
2015/0038859	A1	2/2015	Dalvi et al.	2016/0066879	A1	3/2016	Telfort et al.
2015/0045637	A1	2/2015	Dalvi	2016/0072429	A1	3/2016	Kiani et al.
2015/0051462	A1	2/2015	Olsen	2016/0073967	A1	3/2016	Lamego et al.
2015/0080754	A1	3/2015	Purdon et al.	2016/0081552	A1	3/2016	Wojtczuk et al.
2015/0087936	A1	3/2015	Al-Ali et al.	2016/0095543	A1	4/2016	Telfort et al.
2015/0094546	A1	4/2015	Al-Ali	2016/0095548	A1	4/2016	Al-Ali et al.
2015/0097701	A1	4/2015	Al-Ali et al.	2016/0103598	A1	4/2016	Al-Ali et al.
2015/0099950	A1	4/2015	Al-Ali et al.	2016/0113527	A1	4/2016	Al-Ali et al.
2015/0099951	A1	4/2015	Al-Ali et al.	2016/0143548	A1	5/2016	Al-Ali
				2016/0166210	A1	6/2016	Al-Ali

* cited by examiner




FIG. 1




FIG. 2




FIG. 3A

PaO₂ vs SaO₂ sensitive to pH, Temp




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E




FIG. 3F




FIG. 4




FIG. 5




FIG. 6





FIG. 8A






FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11

HYPERSATURATION INDEXPRIORITY CLAIM TO RELATED
PROVISIONAL APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 13/865,081, filed Apr. 17, 2013, entitled "Hypersaturation Index," which claims priority benefit under 35 U.S.C. §119(e) of U.S. Provisional Application Ser. No. 61/719,866, filed Oct. 29, 2012, entitled "Noninvasive Partial Pressure of Oxygen Sensing System," U.S. Provisional Application Ser. No. 61/703,087, filed Sep. 19, 2012, entitled "Noninvasive Partial Pressure of Oxygen Sensing System," and U.S. Provisional Application Ser. No. 61/625,599, filed Apr. 17, 2012, entitled "Noninvasive Partial Pressure of Oxygen Sensing System," the disclosures of which are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to the field of noninvasive oxygen delivery measurement using optical based sensors.

BACKGROUND

The measurement of oxygen delivery to the body and the corresponding oxygen consumption by its organs and tissues is vitally important to medical practitioners in the diagnosis and treatment of various medical conditions. Oxygen delivery is useful, for example, during certain medical procedures, where artificially providing additional oxygen to the patient's blood stream may become necessary. For example, during an intubation procedure, the patient will stop breathing while the procedure is performed. The patient is typically provided with oxygen before the intubation procedure. Because the patient stops breathing during an intubation procedure, the patient's blood oxygen saturation level will fall. In that situation, the medical practitioner must ensure that the patient has sufficient reserves of oxygen in their system before intubation so that during the intubation procedure suffocation is avoided. At the same time, providing oxygen at a high pressure to a patient can cause damage to the alveoli of an adult patient. On the other hand, even normal oxygen levels can or cause blindness in neonatal patients.

The current standard of care is to measure oxygen delivery through the use of a pulse oximeter. Pulse oximeters measure oxygen saturation (SpO_2). SpO_2 represents the percent of available hemoglobin that can chemically bind with oxygen molecules.

Another indicator of oxygen delivery is the partial pressure of oxygen (PaO_2). However, there are currently no reliable ways to measure PaO_2 noninvasively. Invasive PaO_2 measurements require expensive sensors and are known to carry serious side effects that can harm the health of a patient.

SUMMARY

Embodiments of the present disclosure provide a hypersaturation index for measuring a patient's absorption of oxygen in the blood stream after a patient has reached 100% oxygen saturation. This hypersaturation index provides an indication of an increased level of dissolved oxygen in the plasma. This is useful, for example, for patients that are on supplemental oxygen therapy or are on a ventilator or closed-loop positive pressure delivery device. An exces-

sively high level of PaO_2 can be dangerous for most patients. In some patients, for example neonates, a high level of PaO_2 can cause loss of eyesight. Significant damage can occur to the lungs, and in particular, to the alveoli structures in the lungs, if the PaO_2 level is too high.

In another embodiment, a timer is provided that indicates when a hypersaturated patient is likely to return to a baseline saturation level after oxygen administration is stopped. This is useful, for example, during an intubation procedure.

Pulse oximetry is a noninvasive technique which allows the continuous in vivo measurement of arterial oxygen saturation and pulse rate in conjunction with generation of a photoplethysmograph waveform. Measurements rely on sensors which are typically placed on the fingertip of an adult or the foot of an infant. As explained in detail below, the ratio of red and infrared light signals absorbed at the measuring site is calculated (R/IR ratio). Oxygen saturation level is determined using a lookup table that is based on empirical formulas that convert the ratio of red and infrared absorption rates to a SpO_2 value.

A correlation exists between the R/IR ratio and the level of PaO_2 . This relationship between R/IR ratio and PaO_2 levels, however, varies from patient to patient. For example, at the same PaO_2 level, one patient may have a R/IR ratio of 0.55 and another patient may have a reading of 0.45. Therefore, once the absorption level reaches 100%, it becomes difficult for the medical practitioner to assess the patient's condition with respect to PaO_2 and the potential dangers of a high level of PaO_2 . Without the ability to accurately measure the PaO_2 level, medical practitioners are in need of a noninvasive way to monitor a patient's hypersaturation status.

In an embodiment of the present invention, a hypersaturation index is calculated based on the reading of the R/IR ratio at the measurement site. In an embodiment of the invention, a maximum hypersaturation index threshold is determined such that an alarm is triggered when the hypersaturation index reaches or exceeds the threshold. In another embodiment, an alarm is triggered when the hypersaturation index reaches or falls below its starting point when it was first calculated.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawings and following associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims. Corresponding numerals indicate corresponding parts, and the leading digit of each numbered item indicates the first figure in which an item is found.

FIG. 1 illustrates a perspective view of a patient monitoring system in accordance with an embodiment of the disclosure.

FIG. 2 illustrates a block drawing of a patient monitoring system in accordance with an embodiment of the disclosure.

FIG. 3A-3B illustrate graphs of SpO_2 versus PaO_2 .

FIG. 3C illustrates a saturation calibration curve.

FIG. 3D-3E illustrate graphs of the difference between arterial and venous saturation vs. perfusion index.

FIG. 3F illustrates the graph of the ratio of R/IR and PaO_2 vs. time.

FIG. 4 illustrates a graph of SpO_2 versus the R/IR ratio and a hypersaturation index versus the R/IR ratio.

FIG. 5 illustrates a flowchart depicting an embodiment of the invention.

FIG. 6 illustrates a flowchart depicting an embodiment of the invention.

FIG. 7 illustrates a visualization of an indication of hypersaturation according to an embodiment of the invention.

FIG. 8A-8B illustrate visualizations of indications of hypersaturation according to an embodiment of the invention.

FIGS. 9A and 9B illustrate a timer display illustrating when a hypersaturated patient will return to a normal saturation level.

FIGS. 10A and 10B illustrate an alternative embodiment of a timer display.

FIG. 11 illustrates another alternative embodiment of a timer display.

DETAILED DESCRIPTION

Aspects of the disclosure will now be set forth in detail with respect to the figures and various embodiments. One of skill in the art will appreciate, however, that other embodiments and configurations of the devices and methods disclosed herein will still fall within the scope of this disclosure even if not described in the same detail as some other embodiments. Aspects of various embodiments discussed do not limit the scope of the disclosure herein, which is instead defined by the claims following this description.

Turning to FIG. 1, a patient monitoring system 100 is illustrated. The patient monitoring system 100 includes a patient monitor 102 attached to a sensor 106 by a cable 104. The sensor monitors various physiological data of a patient and sends signals indicative of the parameters to the patient monitor 102 for processing. The patient monitor 102 generally includes a display 108, control buttons 110, and a speaker 112 for audible alerts. The display 108 is capable of displaying readings of various monitored patient parameters, which may include numerical readouts, graphical readouts, and the like. Display 108 may be a liquid crystal display (LCD), a cathode ray tube (CRT), a plasma screen, a Light Emitting Diode (LED) screen, Organic Light Emitting Diode (OLED) screen, or any other suitable display. A patient monitoring system 102 may monitor oxygen saturation (SpO₂), hypersaturation, perfusion index (PI), pulse rate (PR), hemoglobin count, and/or other parameters.

FIG. 2 illustrates details of a patient monitoring system 100 in a schematic form. Typically a sensor 106 includes energy emitters 216 located on one side of a patient monitoring site 218 and one or more detectors 220 located generally opposite. The patient monitoring site 218 is usually a patient's finger (as pictured), toe, ear lobe, or the like. Energy emitters 216, such as LEDs, emit particular wavelengths of energy, typically red and infrared light signals, through the flesh of a patient at the monitoring site 218, which attenuates the energy. The detector(s) 220 then detect the attenuated energy and send representative signals to the patient monitor 102 for processing. The patient monitor 102 includes processing board 222 and a host instrument 223. The processing board 222 includes a sensor interface 224, signal processor(s) 226, and an instrument manager 228.

The host instrument typically includes one or more displays 108, control buttons 110, a speaker 112 for audio messages, and a wireless signal broadcaster 234. Control buttons 110 may comprise a keypad, a full keyboard, a track wheel, and the like. A patient monitor 102 can include buttons, switches, toggles, check boxes, and the like implemented in software and actuated by a mouse, trackball, touch screen, or other input device.

The sensor interface 224 receives the signals from the sensor 106 detector(s) 220 and passes the signals to the

processor(s) 226 for processing into representations of physiological parameters. These are then passed to the instrument manager 228, which may further process the parameters for display by the host instrument 223. The processor(s) 226 may also communicate with a memory 230 located on the sensor 106; such memory typically contains information related to the properties of the sensor that may be useful in processing the signals, such as, for example, emitter 216 energy wavelengths. The elements of processing board 222 provide processing of the sensor 106 signals. Tracking medical signals is difficult because the signals may include various anomalies that do not reflect an actual changing patient parameter. Strictly displaying raw signals or even translations of raw signals could lead to inaccurate readings or unwarranted alarm states. The processing board 222 processing generally helps to detect truly changing conditions from limited duration anomalies. The host instrument 223 then is able to display one or more physiological parameters according to instructions from the instrument manager 228, and caregivers can be more confident in the reliability of the readings.

Physiology Background

When oxygen molecules come into contact with blood, the majority of the oxygen molecules are bound to the hemoglobin in red-blood cells and a small portion is dissolved directly in the blood plasma. Both of these processes are driven by the partial pressure of oxygen. In the lung, oxygen diffuses across the alveolar membrane, and then the red cell membrane in lung capillaries. When an oxygen molecule encounters a molecule of hemoglobin, it wedges itself between the iron atom and a nitrogen atom attached to the globin chain. This helps to hold the heme group in place in the protein. One molecule of hemoglobin with its four heme groups is capable of binding four molecules of diatomic oxygen, O₂. The pigment of the oxygen loaded heme group, which is called oxyhemoglobin, is a brilliant red color. This is typically the color of arterial blood. Pressure from dissolved oxygen in plasma and in the surroundings in the red cell helps to keep the oxygen on its binding site.

As the blood circulates to the periphery, the small amount of plasma dissolved oxygen is consumed first by cells in organs and tissues, which causes a drop in the partial pressure of oxygen. This release in pressure makes available the much larger reservoir of heme-bound oxygen which begins a sequential unloading of its four oxygen molecules. At the most, under normal circumstances only 3 molecules of oxygen are unloaded. Partially or fully unloaded hemoglobin is called deoxyhemoglobin. It is a dark blue to purplish color. This is also the typical color of venous blood.

There is a general relationship between the oxygen saturation in blood and the partial pressure of oxygen. This nonlinear relation is described by the oxygen dissociation curve as shown in FIG. 3A. FIG. 3A illustrates a graph of SaO₂ versus the partial pressure of oxygen dissolved in the arterial blood, PaO₂. As the partial pressure of oxygen in the arterial blood increases, the percentage of oxygen saturation of the hemoglobin will increase. After the SaO₂ level reaches 100%, the PaO₂ level continues to rise, but the SaO₂ level will not rise further. Thus, although it is possible to estimate PaO₂ levels when SaO₂ is below 100%, as illustrated in FIG. 3A, after a certain point, very large changes in the PaO₂ will produce little change in the SaO₂. A patient whose physiology falls on the first part of the curve is commonly referred to as the Hypoxic. As can be seen from FIG. 3A, there is a high sensitivity around PaO₂=30 mmHg, i.e. the slope is large. A patient whose physiology falls on the

second part of the curve where SaO₂ begins to level off is Normoxic. In the last portion of the curve, where SaO₂ has reached 100%, a patient is considered Hyperoxic.

FIG. 3B illustrates a graph showing the potential shift in the disassociation curve based on an individual patients response. For example a left shift may occur with decreased temperature, decreased 1,3-diphosphoglycerate (2,3DPG), increased pH, or higher CO in the blood. As another example, a right shift will occur with reduced affinity, increased temperature, increased 2,3-DPG and decreased pH. Thus, there is some-uncertainty when determining PaO₂ based on the SaO₂ measurement. This uncertainty can be reduced if the pH and temperature are given as inputs to the device where an appropriate curve may be selected.

Oxygen Consumption

The following oxygen content equation relates the amount of oxygen present in the blood given certain hemoglobin concentration (tHb) and partial pressure of oxygen (PaO₂)

$$\text{ContO}_2(\text{O}_2 \text{ mL/dL}) = \text{tHb}(\text{gramHb/dL}) \cdot 1.34 (\text{ml O}_2/\text{gramHb}) \cdot \text{SaO}_2 + 0.0031 (\text{ml O}_2/\text{mmHg/dL}) \cdot \text{PaO}_2(\text{mmHg}) \quad \text{Eq. 1}$$

Alternatively, the Oxygen Content can be measured directly using a Masimo Rainbow Pulse Oximeter available from Masimo Corporation of Irvine, Calif.

Tissues need a requisite amount of O₂ molecules for metabolism. Under steady state conditions the O₂ consumption is fairly constant. In order to quantify the relationship between oxygen transport and its consumption the Fick principle can be applied. The essence of the Fick principle is that blood flow to an organ can be calculated using a marker substance if the following information is known:

Amount of marker substance taken up by the organ per unit time

Concentration of marker substance in arterial blood supplying the organ

Concentration of marker substance in venous blood leaving the organ

In Fick's original method, the "organ" was the entire human body and the marker substance was oxygen.

This principle may be applied in different ways. For example, if the blood flow to an organ is known, together with the arterial and venous concentrations of the marker substance, the uptake of marker substance by the organ may then be calculated.

As discussed above, hemoglobin and plasma are the main oxygen vectors in the blood. The oxygen content equation can be combined with the Fick principle to describe oxygen consumption and its relationship to blood flow as shown below in Eq.2.

$$\text{OC} = \text{Ca} [1.34 \cdot \text{tHb} \cdot (\text{SaO}_2 - \text{SvO}_2) + 0.0031 \cdot (\text{PaO}_2 - \text{PvO}_2)] \quad \text{Eq. 2}$$

Where OC is Oxygen consumption (mL/min), Ca is Cardiac output (i.e. local blood flow at the test site (dL/min)), tHb is the Total hemoglobin (gram/dL), SaO₂ is Arterial saturation fraction (0-1.0), SvO₂ is Venous saturation fraction (0-1.0), PaO₂ is the Partial pressure of oxygen in the arterial blood (mmHg), PvO₂ is the Partial pressure of oxygen in the venous blood (mmHg), 1.34 represents the HbO₂ carrying capacity (mL O₂/gram Hb), and 0.0031 represents O₂ solubility coefficient in blood (mL O₂/dL). Noninvasive Oxygen Saturation Measurement

Pulse oximetry was invented by Dr. Ayogi in the 1972 as a technique to measure arterial oxygen saturation noninvasively. Dr. Ayogi was able to isolate the arterial pulse absorption from tissue, bone and cartilage absorptions by looking at a signal synchronous with the heartbeat reflecting

the local blood flow at the measurement site. This signal is called the photo-plethysmograph and it can be isolated by the use of a high-pass filter. By exploiting the predictable relationship between arterial oxygen saturation and light absorption through a vascular bed, the arterial blood oxygen saturation (SpaO₂) can be calculated noninvasively. Note that the addition of a small p to SaO₂ to denote calculation from an arterial pulse. It can be shown that the use of two distinct light sources, Red (R)=660 nm and Infrared (IR)=910 nm, a pulse oximeter can calculate the oxygen saturation noninvasively by relating a ratio=R (AC/DC)/IR (AC/DC) to the hemoglobin oxygen saturation through a typical pulse oximeter calibration curve shown in FIG. 3C. We will refer to this ratio as (R/IR) ratio.

Modifying Eq. 2, if (SaO₂—SvO₂) is replaced with βSat, (PaO₂—PvO₂) replaced with ΔP, Ca replaced with the local blood flow (BF), the oxygen consumption is set to a constant and the equation is solved for BF, Eq. 3 results:

$$\text{BF} = \text{Const} / [1.34 \cdot \text{tHb} \cdot \beta\text{Sat} + 0.0031 \cdot \beta\text{P}] \quad \text{Eq. 3}$$

Eq. 3 shows an inverse relationship between blood flow and the arterio-venous saturation difference, ΔSat, as well as arterio-venous O₂ partial pressure difference (ΔP). At normal inspired oxygen levels, the majority of the oxygen is supplied by the hemoglobin. But when the concentration of inspired oxygen is raised, its partial pressure increases, hence ΔP, and more oxygen is delivered to the tissue through the O₂ dissolved in the plasma. Based on Eq. 3, if we consider a digit where a pulse oximeter probe is placed, the increase of inspired oxygen partial pressure will lead to a decrease in the arterio-venous ΔSat. This is true whenever the oxygen consumption is relatively constant.

In a vascular bed the arterial vasculature is coupled mechanically to the venous vasculature through the tissues. Although this coupling is small, the optical arterial pulse, e.g. photo-plethysmograph, has invariably a small venous component. This component is not fixed across subjects but its average is indirectly calibrated for in the saturation calibration curve. Its effect on the arterial pulse is proportional to the coupling size as well as the difference between the arterial and venous saturations at the site. Let us consider a typical subject at room-air saturation of 98%. Looking at the saturation calibration curve of FIG. 3C, a (R/IR) ratio of 0.53 corresponds to 98% saturation. If the inspired oxygen concentration is increased beyond the normal O₂=21%, the (R/IR) ratio continues to drop below 0.53. An example is shown in FIG. 3F where the ratio starts at 0.43 and goes down to 0.43. It can even reach a level as low as 0.3 on some subjects at an inspired O₂=100%.

This behavior may be explained by the reduction in the optical effect of venous coupling as the delta saturation between the arterial and the venous is reduced due to the increase in availability of plasma oxygen. Under this condition, the venous blood will look, optically, a lot like the arterial blood. Hence, the size of the Red photo-plethysmograph signal will shrink with respect to the IR indicating a shrinking βSat, i.e. higher venous saturation. In 1995, Masimo Corporation (Masimo) introduced a new technique for calculation the venous oxygen saturation (SpvO₂) by introducing an artificial pulse into the digit (see, e.g., U.S. Pat. No. 5,638,816, incorporated herein by reference). By using a pulse oximeter with a probe and a subject's digit, a continuous measure of SpaO₂ and SpvO₂ can be calculated. The blood perfusion index (PI) is used as a proxy for the blood flow to the digit. FIG. 3D depicts such an inverse relationship between blood flow (BF) and arterio-venous saturation βSat.

FIG. 3E depicts the effect of increasing the inspired O₂ concentration on the calculated β Sat. As expected there is a commensurate reduction in the β Sat with the increase of oxygen concentration. The arterio-venous β Sat will continue to decrease if the oxygen pressure is increased beyond atmospheric pressure. However, a point of diminishing return will be reached where no more change is possible. At that point the R/IR ratio will stop changing as shown in FIG. 3F. The increase in PaO₂ can be indirectly monitored beyond the normal 100 mmHg by looking at the effects of shrinking β Sat. This cannot be done by looking at the SaO₂ as it will plateau at 100%.

FIG. 4 illustrates a graph of SpO₂ saturation percentage **400** versus the R/IR ratio **401** according to an embodiment of the invention. In the illustrated example, the R/IR ratio is at 0.5 when the SpO₂ maxes out at 100%. While the SpO₂ level will max out at 100% saturation, the R/IR ratio continues to drop when more oxygen is dissolved in the blood. An embodiment of the invention calls for calculating a hypersaturation index **402** based on the R/IR ratio after the point **403** where the R/IR ratio translates to a SpO₂ level of 100% saturation. This hypersaturation index **402** assists medical practitioners in exercising their judgment in ensuring that the patient's blood is not too oversaturated with oxygen. In another embodiment, the hypersaturation index is calculated in response to a user signal, i.e., not necessarily at the point where the SpO₂ level is at 100% saturation.

Determining a level of hypersaturation is particularly important in a variety of patient types. For example, patients on supplemental O₂ titration are at risk of complications caused by hypersaturation. Patients on a ventilator or where FiO₂ therapy is given to the patient are also at risk. Further, closed loop positive pressure O₂ delivery or FiO₂ delivery devices also place a patient at risk of hypersaturation. This may include, for example, CPAP machines or those suffering obstructive sleep apnea.

In an embodiment of the invention, the patient's oxygen saturation level SpO₂ is determined and monitored. When the saturation level reaches 100%, an indication of rising oxygen levels, such as a hypersaturation index, is calculated. The indication of rising oxygen levels may also be displayed on an output device such as the display **108** in FIG. 1. FIG. 5 is a flowchart that illustrates this embodiment of the invention. In this embodiment, the patient's blood oxygen saturation level SpO₂ is determined at step **500**. If the blood oxygen saturation level maxes out at 100% at step **520**, an indication of hypersaturation is calculated at step **530** and displayed at step **540**.

In another embodiment of the invention, illustrated in FIG. 6, the patient's oxygen saturation level SpO₂ is determined and stored at step **620** in response to a signal from the user at step **610**. The signal typically indicates that a medical procedure is about to begin. A base hypersaturation index value is then calculated at step **630** based on the stored oxygen saturation level and the R/IR ratio. The hypersaturation index is then monitored at step **640** as the patient's oxygen saturation level changes. Next, an alarm trigger is generated at step **660** when the hypersaturation index value is less than or equal to the base hypersaturation index value as determined in step **650**. Finally, an alarm is activated at step **670** in response to the alarm trigger.

In an alternative embodiment, the oximeter monitors a patient and automatically determines a baseline oxygen saturation level and/or baseline ratio from stable measurements taken when the oximeter first begins measurements. The oximeter can indicate that a baseline measurement has been determined or can indicate that it is unable to determine

a baseline measurement if stable measurements cannot be obtained. Once a baseline measurement is obtained, the oximeter will monitor the patient for an inflection point in the saturation and ratio calculations. If the oximeter finds an inflection point where the patient's oxygen saturation begins to rise and/or ratios begin to fall, it will determine that oxygen is being administered to the patient. In this way, a caregiver is not required to push a button or otherwise indicate the start of a procedure or the start oxygen administration. Along the same lines, once a patient is hypersaturated, the oximeter will monitor the saturation level and/or ratio calculations of the patient for an inflection point indicating that oxygen is no longer being administered to the patient. Again the oximeter will alarm when the oxygen saturation values and/or ratios return to their normal baseline levels.

In yet another embodiment of the invention, a maximum hypersaturation index value is also calculated and stored in response to a user signal. In this embodiment, an alarm trigger is generated when the monitored hypersaturation index value is more than or equal to the maximum hypersaturation index value.

In an alternative embodiment, a visual oxygen hypersaturation alarm is activated. The oxygen hypersaturation alarm may include text that indicates that the oxygen hypersaturation index has dropped below the base hypersaturation index value. In another embodiment, the alarm may include text that indicates that the oxygen hypersaturation index has exceeded a threshold value. The visual oxygen hypersaturation alarm may be accompanied or replaced by an audio alarm in certain embodiments.

FIG. 7 illustrates an example of a visualization of an indication of hypersaturation according to an embodiment of the invention. This visualization can be displayed on a display, such as the display **108** in FIG. 1. In the illustrated embodiment, the indicator is displayed as a speedometer-type visualization. The display includes a pointer **700** that points to the current value of the hypersaturation indicator. The value, for example, can be on a scale of 0-100 or 0-10 to differentiate from oxygen saturation. In one embodiment, the spectrum of possible levels may be indicated by various shades or colors. For example, the low range of values may be indicated by an area **701** that is green in color, the medium range in values may be indicated by an area **702** that is orange in color, and the high range in values may be indicated by an area **703** that is red in color.

FIG. 8A illustrates another example of a visualization of an indication of hypersaturation according to an embodiment of the invention. This visualization can also be displayed on a display, such as the display **108** in FIG. 1. In the illustrated embodiment, the hypersaturation indicator is displayed as a bar **800**. In one embodiment, the size of the area of the bar that is shaded or colored depends on the value of the hypersaturation indicator. For example, a low value may be represented by a small shaded area below the "L" level **801**. A medium value may be represented by a larger shaded area that remains below the "M" level **802**. Finally, a high value may be represented by an even larger shaded area that can cover the entirety of the bar up to the "H" level **803**.

FIG. 8B illustrates yet another example of a visualization of an indication of hypersaturation. The displayed graph **820** illustrates hypersaturation on a scale of 0-100%. The line **821** illustrates an estimated hypersaturation value. The shaded area **823** illustrates the variability of the hypersaturation index. In other words, each patient's physiology is different and depending patient, their hypersaturation may not exactly follow the population average. This is explained in

more detail, for example, with respect to FIG. 3B. Thus, the shaded area 823 provides an indication of the uncertainty in the estimate 821. This provides a care provider with a better indication of the actual hypersaturation that the patient is experiencing. In the embodiment of FIG. 8B, 0% represents no detectable oxygen reserve, or no indication of hypersaturation. 100% indicates a maximum detectable reserve or a maximum hypersaturation.

FIG. 9A illustrates an embodiment of a hypersaturation timer 900. A hypersaturation timer 900 is useful, for example, during procedures such as a patient intubation when the patient is forced to stop breathing. The timer provides an indication of the amount of time a care giver has before the patient returns from a hypersaturated state to a baseline saturation state. The timer includes a countdown indications 901-905. In the embodiment of FIG. 9A, the countdown begins at about 60 seconds and counts down to zero. When the counter is initially started, the amount of time a patient will take to return to a baseline saturation state is relatively difficult to determine. Thus, the timer 900 provides a range of time left which is illustrated by shaded area 907. The shaded area moves clockwise around the timer indicating a range of time left before the patient reaches a baseline state. As time goes by, the amount of time a patient will take to return to a baseline saturation state becomes more predictable based on how quickly the ratios change. Thus, as illustrated in FIG. 9B, the range indicated by the shaded area 910 becomes smaller.

FIG. 10 illustrates another embodiment of a timer 1000. Similar to FIGS. 9A and B, timer 1000 has a count-down range 1002 that decreases as time expires and the time in which a patient returns to their base line saturation becomes more certain.

In another embodiment not shown, a simple digital count-down clock could also be used to indicate the amount of time left for a hypersaturation patient to return to their baseline saturation level. The count-down clock can indicate a range or it can simple indicate a number and speed up or slow down based on the rate of return experienced by the patient.

FIG. 11 illustrates an embodiment count down display of an oxygen reserve, or the time left for a hypersaturation patient to return to baseline saturation. Put in other terms, the time in seconds starts increasing from zero as a subject transitions from normoxia to hyperoxia. The display then decreases when the subject transitions from the Hyperoxic state to the Normoxic state. The display of FIG. 11 includes an arc indicator, for example, arc indicators 1101, 1102, and 1103. The indicators are arced in order to show the uncertainty range in the time left in the display. Although the arcs 1101, 1102, and 1103 are all illustrated on the display for illustration and explanation purposes, it is to be understood that during measurement, only a single arc is displayed which according to the relative time

Although the foregoing has been described in terms of certain specific embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. Moreover, the described embodiments have been presented by way of example only, and are not intended to limit the scope of the disclosure. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. Accordingly, other combinations, omissions, substitutions, and modifications will be apparent to the skilled artisan in view of the disclosure herein. Thus, the present disclosure is not limited by the disclosed embodiments, but is defined by reference to the appended claims. The accompanying claims and their equivalents are intended

to cover forms or modifications as would fall within the scope and spirit of the disclosure.

What is claimed is:

1. A method of providing an indication of an oxygenation of blood of a non-invasively monitored patient different from oxygen saturation, wherein said oxygen saturation is a measure of a percentage of available carriers in the blood that are bound to oxygen molecules at a time of measurement acquisition, the method comprising:
 - using an electronic light source including one or more light emitters, emitting at least a plurality of wavelengths of light into a portion of a body of the patient;
 - using an electronic light detector, detecting the light after attenuation of the body, said attenuation responsive to said oxygenation of said blood, and outputting one or more signals from said light detector, said one or more signals responsive to said attenuation;
 - processing said one or more signals using one or more signal processors to electronically:
 - calculate a first index responsive to said percentage of said carriers bound to oxygen, said first index being said measure of said oxygen saturation, and
 - calculate a second index responsive to a quantity of oxygen dissolved in the blood of a patient and not bound to any of said carriers while the patient is in a hyperoxic state, said second index providing different information to a caregiver than said first index, wherein said second index is calculated based on a ratio of information from at least a first of the plurality of wavelengths and information from at least a second of the plurality of wavelengths during the hyperoxic state of the patient; and
 - electronically displaying at least a value responsive to said second index.
2. The method of claim 1, wherein the displaying comprises displaying an oxygen hypersaturation index.
3. The method of claim 2, wherein the hypersaturation index is indicative of the partial pressure of oxygen.
4. The method of claim 2, wherein the displaying comprises displaying a graph of the oxygen hypersaturation index.
5. The method of claim 1, wherein the displaying comprises generating an alarm in response to the value responsive to said second index crossing a threshold.
6. The method of claim 5, wherein the displaying comprises displaying an amount of time after oxygen administration is stopped until the value responsive to said second index reaches the threshold.
7. The method of claim 6, wherein the amount of time becomes more certain as time expires.
8. The method of claim 1, wherein the displayed value comprises one or more of a number, a fillable bar where a fill is responsive to said dissolved oxygen, or a color responsive to said dissolved oxygen.
9. The method of claim 1, further comprising displaying a second value responsive to said first index.
10. The method of claim 9, wherein the displayed second value comprises one or more of a numeric percentage, a fillable bar where a fill is responsive to said percentage, or a color responsive to said percentage.
11. The method of claim 1, wherein the calculating of the first and/or second indices comprises using an oxygen saturation curve, wherein the oxygen saturation stays the same within a predetermined range of an R/IR ratio.
12. A system for determining an estimate of an oxygen saturation of a patient and an additional estimate of a non-invasively measured oxygen reserve of said patient,

11

said oxygen saturation being a measure of a percentage of available carriers in blood that are bound to oxygen molecules at a time of measurement acquisition and said oxygen reserve being oxygen dissolved in the blood of a patient during a hyperoxic state of the patient and different from an amount of dissolved oxygen corresponding to said estimate of said oxygen saturation, the system comprising:

an input of an electronic physiological monitor, said input configured to receive one or more signals responsive to light of at least a plurality of wavelengths attenuated by body tissue of the patient, said one or more signals output from a light detector configured to detect said attenuated light;

one or more physiological hardware processors of said electronic physiological monitor, the one or more processors configured to electronically:

calculate a first index responsive to said percentage of said carriers bound to oxygen, said first index being said measure of said oxygen saturation, and

calculate a second index responsive to said dissolved oxygen, wherein said second index is responsive to a ratiometric calculation, said ratiometric calculation including a denominator responsive to portions of said one or more signals that were responsive to at least one of said plurality of wavelengths during the hyperoxic state of the patient and a numerator responsive to portions of said one or more signals

12

that were responsive to at least another of said plurality of wavelengths during the hyperoxic state of the patient; and

a display electronically providing at least a visual indicia of said second index.

13. The system of claim 12, wherein the displayed visual indicia of said second index is an oxygen hypersaturation index.

14. The system of claim 13, wherein the hypersaturation index is indicative of the partial pressure of oxygen.

15. The system of claim 12, wherein the displayed visual indicia of said second index comprises a graph of an oxygen hypersaturation index.

16. The system of claim 12, further comprising an alarm configured to generate an alarm indication in response to the displayed visual indicia of said second index crossing a threshold.

17. The system of claim 12, wherein said visual indicia comprises one or more of a number, a fillable bar where a fill is responsive to said dissolved oxygen, or a color responsive to said dissolved oxygen.

18. The system of claim 12, wherein the display is configured to electronically provide a second visual indicia of said first index.

19. The system of claim 18, wherein said second visual indicia comprises one or more of a numeric percentage, a fillable bar where a fill is responsive to said percentage, or a color responsive to said percentage.

* * * * *

专利名称(译)	过饱和指数		
公开(公告)号	US9775546	公开(公告)日	2017-10-03
申请号	US14/852356	申请日	2015-09-11
[标]申请(专利权)人(译)	梅西莫股份有限公司		
申请(专利权)人(译)	Masimo公司		
当前申请(专利权)人(译)	Masimo公司		
[标]发明人	DIAB MOHAMED K IYENGAR PRASHANTH SAMPATH ANAND AL ALI AMMAR		
发明人	DIAB, MOHAMED K. IYENGAR, PRASHANTH SAMPATH, ANAND AL-ALI, AMMAR		
IPC分类号	A61B5/1455 A61B5/00 A61B5/0205		
CPC分类号	A61B5/7405 A61B5/746 A61B5/14552 A61B5/0205 A61B5/14551 A61B5/7282 A61B5/743 A61B5/6826 A61B2562/0238 A61M2230/205		
优先权	61/719866 2012-10-29 US 61/703087 2012-09-19 US 61/625599 2012-04-17 US		
其他公开文献	US20160000362A1		
外部链接	Espacenet USPTO		

摘要(译)

本公开的实施方案提供了一种过饱和指数，用于在患者达到100%氧饱和度后测量患者对血流中氧的吸收。该过饱和指数提供了患者的氧分压的指示。在本发明的一个实施方案中，基于测量位点处两种不同波长的能量的吸收比计算超饱和指数。在本发明的一个实施例中，确定最大超饱和指数阈值，使得当超饱和指数达到或超过阈值时触发警报。在另一个实施例中，当超饱和指数达到或低于其首次计算时的起始点时触发警报。

